Treatment of colorectal cancer (CRC) has developed considerably over the past 10 years, especially in the areas of
targeted therapeutics and biomarker development. Targeted therapies, which include monoclonal antibodies and
small molecule inhibitors, directed at the vascular endothelial growth factor pathway and the epidermal growth
factor pathway are now key players in the treatment of colorectal cancer. Preclinical and clinical studies have
shown that the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid
therapeutic targets for patients with CRC.
This review focuses on the evidence supporting the current role of targeted therapy and the strategy of combining
chemotherapy and biological therapy in the treatment of metastatic colorectal cancer.
PDF Links
Full text via DOI
Download Citation 
